Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
Jaekwon SeokHee Jeong KwakYeonjoo KwakMoonjung LeeKyoung Sik ParkAram KimSsang-Goo ChoPublished in: Journal of translational medicine (2023)
Dutasteride inhibited testosterone-induced BCa progression dependent on SLC39A9 in AR-negative BCa and repressed oncogenic signaling pathways, including those of metalloproteases, p21, BCL-2, NF-KB, and WNT. Our results also suggest that SRD5A1 plays a pro-oncogenic role in BCa. This work provides potential therapeutic targets for the treatment of BCa.
Keyphrases
- benign prostatic hyperplasia
- signaling pathway
- lower urinary tract symptoms
- transcription factor
- prostate cancer
- pi k akt
- stem cells
- diabetic rats
- replacement therapy
- cell proliferation
- high glucose
- oxidative stress
- drug induced
- lps induced
- anti inflammatory
- emergency department
- nuclear factor
- immune response
- risk assessment
- endothelial cells
- combination therapy
- inflammatory response
- human health
- adverse drug